{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:07:37Z","timestamp":1748578057875,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.7759\/cureus.85034","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:22:29Z","timestamp":1748532149000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Prostate Cancer-Related Symptoms and Toxicities Following Stereotactic Body Radiation Therapy: Implications for Future Radionuclide Therapy"],"prefix":"10.7759","author":[{"given":"Diya","family":"Kallam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Gaudian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoya","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ji","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika T","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suy","family":"Simeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Gudenkauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2020.07.004","article-title":"The role of theranostics in prostate cancer","volume":"31","author":"O'Dwyer E","year":"2021","unstructured":"O'Dwyer E, Bodei L, Morris MJ. The role of theranostics in prostate cancer. Semin Radiat Oncol. 2021, 31:71-82. 10.1016\/j.semradonc.2020.07.004","journal-title":"Semin Radiat Oncol"},{"key":"ref2","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli RS","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54:1807-11.","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T","article-title":"Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen","volume":"83","author":"Murphy GP","year":"1998","unstructured":"Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998, 83:2259-69. 10.1002\/(SICI)1097-0142(19981201)83:11&lt;2259::AID-CNCR5&gt;3.0.CO;2-T","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich U","year":"2022","unstructured":"Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022, 15:1292. 10.3390\/ph15101292","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge M","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, et al.. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020, 61:62-9. 10.2967\/jnumed.119.229229","journal-title":"J Nucl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman MS","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, et al.. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19:P825-33. 10.1016\/S1470-2045(18)30198-0","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor O","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al.. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021, 385:1091-103. 10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7150\/thno.87663","article-title":"Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands","volume":"13","author":"Kuo HT","year":"2023","unstructured":"Kuo HT, Zhang Z, Zhang C, et al.. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands. Theranostics. 2023, 13:4559-73. 10.7150\/thno.87663","journal-title":"Theranostics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [(177)Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells Z","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [(177)Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024, 65:1264-71. 10.2967\/jnumed.124.267452","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.2478","article-title":"EQ-5D-3L norms for the European older population: country-specific norms for 15 European countires based on the survey of health, ageing, and retirement in Europe","volume":"26","author":"Buchholz I","year":"2023","unstructured":"Buchholz I, Janssen MF. EQ-5D-3L norms for the European older population: country-specific norms for 15 European countires based on the survey of health, ageing, and retirement in Europe. Value Health. 2023, 26:721-32. 10.1016\/j.jval.2022.09.2478","journal-title":"Value Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264946","article-title":"Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer","volume":"64","author":"Gudenkauf LM","year":"2023","unstructured":"Gudenkauf LM, Chavez MN, Maconi ML, et al.. Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer. J Nucl Med. 2023, 64:869-72. 10.2967\/jnumed.122.264946","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2009.05.009","article-title":"Fatigue among older people: a review of the research literature","volume":"47","author":"Yu DS","year":"2010","unstructured":"Yu DS, Lee DT, Man NW. Fatigue among older people: a review of the research literature. Int J Nurs Stud. 2010, 47:216-28. 10.1016\/j.ijnurstu.2009.05.009","journal-title":"Int J Nurs Stud"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-014-0277-4","article-title":"Proctitis following stereotactic body radiation therapy for prostate cancer","volume":"9","author":"Joh DY","year":"2014","unstructured":"Joh DY, Chen LN, Porter G, et al.. Proctitis following stereotactic body radiation therapy for prostate cancer. Radiat Oncol. 2014, 9:277. 10.1186\/s13014-014-0277-4","journal-title":"Radiat Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen LN","year":"2013","unstructured":"Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:58. 10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0528.2008.00432.x","article-title":"Prevalence of hyposalivation in relation to general health, body mass index and remaining teeth in different age groups of adults","volume":"36","author":"Flink H","year":"2008","unstructured":"Flink H, Bergdahl M, Tegelberg A, Rosenblad A, Lagerl\u00f6f F. Prevalence of hyposalivation in relation to general health, body mass index and remaining teeth in different age groups of adults. Community Dent Oral Epidemiol. 2008, 36:523-31. 10.1111\/j.1600-0528.2008.00432.x","journal-title":"Community Dent Oral Epidemiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.03.004","article-title":"NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors","volume":"105","author":"Beetz I","year":"2012","unstructured":"Beetz I, Schilstra C, van der Schaaf A, et al.. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol. 2012, 105:101-6. 10.1016\/j.radonc.2012.03.004","journal-title":"Radiother Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter?","volume":"59","author":"Ta\u00efeb D","year":"2018","unstructured":"Ta\u00efeb D, Foletti JM, Bardi\u00e8s M, Rocchi P, Hicks RJ, Haberkorn U. PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter?. J Nucl Med. 2018, 59:747-8. 10.2967\/jnumed.118.207993","journal-title":"J Nucl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262543","article-title":"Safety of PSMA-targeted molecular radioligand therapy with (177)Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312)","volume":"62","author":"Calais J","year":"2021","unstructured":"Calais J, Czernin J, Thin P, et al.. Safety of PSMA-targeted molecular radioligand therapy with (177)Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312). J Nucl Med. 2021, 62:1447-56. 10.2967\/jnumed.121.262543","journal-title":"J Nucl Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials","volume":"28","author":"Ramnaraign B","year":"2023","unstructured":"Ramnaraign B, Sartor O. PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials. Oncologist. 2023, 28:392-401. 10.1093\/oncolo\/oyac279","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin NJ","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018, 27:7-22. 10.1002\/hec.3564","journal-title":"Health Econ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00076","article-title":"Demographic and clinical factors associated with health-related quality-of-life profiles among prostate cancer survivors","volume":"20","author":"Potosky AL","year":"2024","unstructured":"Potosky AL, Ahn J, Xia Y, et al.. Demographic and clinical factors associated with health-related quality-of-life profiles among prostate cancer survivors. JCO Oncol Pract. 2024, 20:921-31. 10.1200\/OP.24.00076","journal-title":"JCO Oncol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356454-chronic-prostate-cancer-related-symptoms-and-toxicities-following-stereotactic-body-radiation-therapy-implications-for-future-radionuclide-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:22:30Z","timestamp":1748532150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356454-chronic-prostate-cancer-related-symptoms-and-toxicities-following-stereotactic-body-radiation-therapy-implications-for-future-radionuclide-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.85034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}